GBT Source Solutions®—helping your Oxbryta patients start and stay on treatment as prescribed
Enroll your Oxbryta patients in GBT Source Solutions today
How to enroll:
Complete Prescriber pages 1-2 of the GBT Source Enrollment Form, which includes a valid Oxbryta prescription. Have your patient (or their Authorized Caregiver*) complete and sign the Patient Authorization and Consent Form to receive support from GBT Source Solutions.
*An Authorized Caregiver is someone who is legally authorized to make decisions on behalf of the patient.
GBT Source HCP Portal
Streamline patient enrollment: enroll patient into GBT Source.
HCP completes and sends all necessary enrollment information to GBT Source
Patient completes and signs Authorization Form, and form is sent to GBT Source
GBT Source reviews benefits and coverage requirements
Informs HCP of prior authorization requirements
Informs HCP of appeal requirements, if needed
GBT Source communicates benefit investigation findings to insured patients
Informs patient of out-of-pocket costs and potential support
Informs HCP of discussion with patient and next steps
Fulfillment
GBT Source sends enrollment form (prescription) to specialty pharmacy
Specialty pharmacy contacts patient to schedule shipment
Ongoing refill and adherence services
Specialty pharmacy contacts patient on a regular basis to schedule and send refills
Specialty pharmacy and GBT Source continue ongoing contact with patient to help address access and adherence challenges
Helpful tips to streamline enrollment
Once you’ve talked to your patient about the benefits of enrolling in GBT Source:
Complete all sections of the Prescription/Enrollment Form and sign/enter the date in the appropriate boxes
Verify that patient’s contact and insurance information is correct (you may also include a copy of the front and back of your patient’s insurance card with the Prescription/Enrollment Form)
Provide your contact and alternative office contact details to GBT Source for quick and efficient communication
Make sure your patient (or their Authorized Caregiver) reads, signs, and dates the Patient Authorization and Consent Form
GBT Source Solutions is a resource for your patients that offers access and reimbursement support after Oxbryta has been prescribed
Support for your eligible patients throughout the treatment process
Financial assistance†
Reimbursement support†
Specialty pharmacy
Adherence support
Explore the access and support available to your patients
†Enrolled patients must meet GBT Source eligibility criteria.
Oxbryta has widespread payer coverage nationwide
The GBT Source Commercial Copay Program may cover up to a maximum of $15,000 per calendar year of out-of-pocket expenses related to Oxbryta tablets‡
Patients who do not have health insurance may qualify for the GBT Source Solutions Patient Assistance Program (PAP) for Free Drug.‡ Please call us at (833) 428-4968 for information about this program
For patients with government-funded insurance who need assistance, GBT Source can provide information on independent charitable patient assistance programs. GBT Source does not have any affiliation with these programs nor does GBT determine eligibility
Our team is here to assist you
For your practice/patients
Access Navigators
Answer questions and provide information on access requirements related to Oxbryta, including GBT Source resources, navigating the insurance process, and the Patient Assistance Program
Assist your practice with on-site, in-person support or with virtual, online support
Contact patients who opted in during enrollment to schedule an introductory session to provide an overview of the services provided by GBT Source
For your patients
Care Coordinators provide reimbursement support
Discuss and verify insurance benefits
Determine if prior authorization is necessary
Inform you and your patients (or their Authorized Caregivers) about out-of-pocket costs
Provide information about appeals process if coverage is denied
A Nurse Support Team provides adherence support§
Help your patients start and stay on Oxbryta as prescribed
Provide resources and answer general questions about treatment with Oxbryta
§The Nurse Support team is available to support product adherence, and does not replace a patient’s treatment plan. They do not provide medical advice or case management services.
For your patients/practice
Specialty Pharmacy
Coordinates shipment of Oxbryta once prescribed
Follows up with patients (or their Authorized Caregivers) after shipments are delivered
Monitors prescription refills and requests refill authorization as needed
Notifies you and your patients of any treatment challenges or refill issues
Answers any questions your patients may have (pharmacist available by phone 24/7)
You are now leaving Global Blood Therapeutics’ site and moving to an external website independently operated and not managed by Global Blood Therapeutics. Global Blood Therapeutics assumes no responsibility for the site(s) you're visiting. If you do not wish to leave this site, click Cancel, or click OK to continue.
A message from Dr. Ted W. Love
President and CEO, Global Blood Therapeutics, Inc.
Thank you for visiting the virtual 62nd ASH® Annual Meeting and Exposition!
Thank you for visiting the virtual 62nd ASH® Annual Meeting and Exposition!
We are proud to participate in this important meeting and appreciate your interest in learning more about GBT and Oxbryta® (voxelotor) tablets. We at GBT share your passion and commitment to improving the lives of patients. Together, we can make a difference.
I encourage you to explore our website to learn more about Oxbryta.
NEJM does not hold itself responsible for statements made by any contributor. Statements or opinions expressed in NEJM reflect the views of the author(s) and not the official policy of the Massachusetts Medical Society unless so stated. NEJM reprints are not intended as the sole source of clinical information on this topic. Readers are advised to search the NEJM website at www.nejm.org and other medical sources for relevant clinical information on this topic. Reprints of articles published in NEJM are distributed only as free-standing educational material. They are not intended to endorse or promote any organization or its products or services.
By clicking OK, you will be redirected to a website that is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of that site. If you do not wish to leave this site, click Cancel, or click OK to continue.